LIQUID BIOPSY: THERANOSTICS AND PERSONALIZED ONCOLOGY
Cancer is linked with mutated genes, and the study of tumor-associated genetic alterations is gradually used for diagnostic and treatment purposes. The solid tumors are now obtained from biopsy and/or surgical or biopsy specimens. Tumor cells release circulating free DNA into the blood, but the majority of circulating DNA are often not of cancerous origin, and the detection of cancer-associated alleles in the blood has long been unbearable to achieve. Modern science has overwhelmed these restrictions, making it possible to identify both genetic and epigenetic aberrations. A liquid biopsy (LB) or blood sample can provide the genetic landscape of all cancerous lesions (primary and metastases) as well as offering the opportunity to systematically track genomic evolution. This communication will explore how LB is associated with personalized oncology to predict response to treatments and the development of acquired resistance.
2. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
4. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumor heterogeneity in the clinic. Nature 2013;501:355-64.
5. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancergenetics in the blood. Nat Rev Clin Oncol 2013;10:472.
6. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumorheterogeneity, and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
7. Chu D, Park BH. Liquid biopsy: Unlocking the potentials of cell-free DNA. Virchows Arch 2017;471:147-54.
8. Jung A, Kirchner T. Liquid biopsy in tumor genetic diagnosis. Dtsch Arztebl Int 2018;115:169-74.
9. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016;6:479-91.
10. Diaz LA, Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
11. Oellerich M, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, et al. Using circulating cell-free DNA to monitorpersonalized cancer therapy. Crit Rev Clin Lab Sci 2017;54:205-18.
12. Kirchner T. Liquid biopsy in tumor genetic diagnosis. Dtsch Arztebl Int 2018;115:169-74.
13. De Rubis G, Krishnan SR, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci 2019;40:172-86.
14. Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing fornon-small cell lung cancer? Ann Transl Med 2017;5:46.
15. Mathai RA, Vidya RV, Reddy BS, Thomas L, Udupa K, Kolesar J. Potential utility ofliquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors: Implications in the precision oncology. J Clin Med 2019;8:E373.
16. Takahashi RU, Prieto-Vila M, Hironaka A, Ochiya T. The role of extracellular vesiclemicroRNAs in cancer biology. Clin Chem Lab Med 2017;55:648-56.
17. Soda N, Rehm BH, Sonar P, Nguyen NT, Shiddiky MJ. Advanced liquid biopsytechnologies for circulating biomarker detection. J Mater Chem B 2019;7:6670-704.
18. Wu J, Hu S, Zhang L, Xin J, Sun C, Wang L, et al. Tumor circulome in the liquid biopsies for cancer diagnosisand prognosis. Theranostics 2020;10:4544-56.
19. Bielski CM, Donoghue MT, Gadiya M, Hanrahan AJ, Won HH, Chang MT, et al. Widespread selection for oncogenicmutant allele imbalance in cancer. Cancer Cell 2018;34:852-62.
This work is licensed under a Creative Commons Attribution 4.0 International License.